Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hwangryunhaedoktang (HHT) is a traditional Korean herbal medicine (known as Huang-Lian-Jie-Du-Tang in China and Orengedokuto in Japan) composed of four botanical ingredients: Scutellariae Radix, Coptidis Rhizoma, Phellodendri Cortex, and Gardeniae Fructus. It is approved by the Korean Food and Drug Administration (KFDA) for the treatment of various conditions including fever, inflammation, gastritis, and hypertension. HHT is currently being investigated in a Phase III clinical trial, sponsored by the Korea Health Industry Development Institute (KHIDI), for its efficacy in treating adult patients with atopic dermatitis. The formulation is believed to work by suppressing pro-inflammatory cytokines (such as TNF-alpha, IL-4, and IL-5) and inhibiting the NF-kappaB signaling pathway, thereby reducing skin inflammation and pruritus. It is administered orally as a decoction or granule extract, and topical applications have also been explored for skin barrier repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hwangryunhaedoktang.